ARTIDIS Launches Groundbreaking ANGEL Study With Over 2,700 Participants: Transforming Breast Cancer Diagnosis and Personalized Therapy Optimization at the Patient's Bedside
The study aims to enroll over 2,700 patients, generating comprehensive insights into all breast cancer subtypes.
- The study aims to enroll over 2,700 patients, generating comprehensive insights into all breast cancer subtypes.
- Dr. Alastair Thompson commented, “As a breast surgeon, I believe this study holds immense importance for breast cancer patients.
- The ANGEL study specifically addresses the key challenges of personalized diagnosis and treatment decision-making, particularly in the field of neoadjuvant therapy.
- Ensuring patients receive the best possible treatment from the start is crucial for improving outcomes for breast cancer patients.